Summary In this population-based elderly cohort, participants using selective serotonin reuptake inhibitor (SSRI) antidepressants have an increased risk of falls and fractures notably when the treatment was continued over 4 years. Among the various SSRI types, citalopram only was at significant risk for falls and fluoxetine for fractures. Introduction Increased risk of falls and fractures has been reported in elderly users of SSRIs. However, biases were insufficiently addressed notably temporality between exposure and outcome and confounding by residual depression. Our objective was to examine the associations between SSRIs and fall or fracture incidence focusing on their chronic use and different types of SSRIs. Methods The population-based cohort included participants aged 65 years and above, who had not fallen before inclusion (n = 6599) or were free of recent fracture (n = 6823) and were followed up twice over 4 years. New fall and fracture events were self-reported and defined as at least two falls and one fracture, respectively, during the previous 2 years. SSRI users were compared with those taking no antidepressants. Hazard ratios (HRs) were estimated using Cox models with delayed entry and adjusted for many confounders including residual depressive symptoms. Results Incidence of falls was 19.3 % over 4 years and that of fractures 9.5 %. After multi-adjustment, SSRI intake was significantly associated with a higher risk of falls (HR, 95 % CI = 1.58, 1.23-2.03) and fractures (HR, 95 % CI = 1.61, 1.16-2.24). The risks were significantly increased by 80 % in those continuing the treatment over 4 years. Citalopram intake only was at significant risk for falls and fluoxetine for fractures. Conclusions In this large community-dwelling elderly sample, SSRI users were at higher risk of falls and fractures. This association was not due to reverse causality or residual depressive symptoms. Different SSRI drugs may have specific adverse effects on falls and fractures.
Introduction
Antidepressants are among the most commonly prescribed drugs in the Western world, with an annual rate of treatment of 10.1 per 100 persons in the US general population and 13.7 in the elderly [1] . While there are arguments supporting antidepressant effectiveness and favorable benefit-risk ratio for major depression [2] , a much lower efficacy has been found for moderate depression [3] . Data on depression in elderly people are scarce despite specific characteristics including the chronicity of symptoms [4] , frequent comorbidities, and the high prevalence of subsyndromal depression [5] which may be inadequately treated. Overtreatment of subsyndromal depression may increase risk of drug interactions and adverse reactions as aging is also associated with pharmacodynamic alterations (decreased renal clearance, altered hepatic metabolism, and increased elimination half-lives).
Several meta-analyses and reviews have reported an increased risk of falls in the elderly [6] [7] [8] [9] as well as fractures [10, 11] , although not consistently. However, biases are insufficiently addressed notably due to a lack or limited consideration of (i) criteria of temporality between exposure and outcome, (ii) pattern of use and treatment chronicity, and (iii) potential confounders and channeling bias (related to underlying burden of physical and mental illness). Separating the effect of depression from the effect of treatment is notably a critical point [11] .
While most of the earlier studies found the class of tricyclic antidepressants (TCAs) to be a risk factor for falls and fractures [8, 12] , more recent studies focused on selective serotonin reuptake inhibitors (SSRIs) [13, 14] which are now the first-line therapy among older patients. Although being considered safer than TCAs, SSRIs have been found to be associated with an increased risk of bone mineral density loss and fracture [10, [15] [16] [17] . This led to consider SSRIs as potentially inappropriate in older adults with a history of falls or fractures [18] . However, two recent systematic reviews concluded that evidence of causation was lacking due to the absence of a demonstrated mediating pathway between SSRIs and falls [19] or osteoporosis [20] . As the effects of antidepressants on falls and fractures in elderly people have never been evaluated in randomized clinical trials, only well-designed analyses of large population-based cohorts can help address these relationships, evaluating long-term effects and taking into account the temporality between exposure and outcome and the main confounders.
The purpose of this study was to examine the longitudinal associations between antidepressant use and (i) falls and (ii) fractures, in a large elderly community-dwelling cohort, for which information on a wide range of potential confounding factors including residual depressive symptoms was available. The analyses focused on SSRIs, their chronic use, and different types of SSRIs.
Method Study sample
Subjects were recruited as part of a multi-site cohort study of community-dwelling persons aged 65 years and over from the electoral rolls of three French cities (Bordeaux, Dijon, and Montpellier) between 1999 and 2001 [21] . The study protocol was approved by the Ethical Committee of the Bicêtre University-Hospital (France) and written informed consent was obtained from each participant. A standardized evaluation with a face-to-face interview and a clinical examination was undertaken at baseline and after 2 and 4 years. The follow-up was then extended but data on falls were not collected after 4 years. Of the 9294 participants included in the cohort, 503 were excluded because of a diagnosis of prevalent or incident dementia. The incidence study on falls was carried out on 6599 participants, after further excluding 600 who declared at least two falls before inclusion, 908 with no follow-up assessments, 214 treated with other antidepressants (only SSRI antidepressants were considered in the present study), and 470 with missing data for at least one of the 16 adjusting covariates. The incidence study on fractures was performed on 6823 participants, after further excluding 613 who declared a fracture before inclusion, 1087 with no follow-up assessments, 216 treated with other antidepressants, and 52 with missing data for at least one of the nine adjusting covariates.
Compared with the analyzed sample for fall incidence, those excluded were older (p < 0.001), more frequently women (p = 0.002), non-smokers (p < 0.001), and taking other medications (p < 0.001). They had more often cognitive, visual, and hearing impairment, physical and activity limitations, fear of falling, daytime sleepiness, depressive symptoms, cardiovascular diseases, osteo-articular pains, and orthostatic hypotension (p < 0.001 for all comparisons).
Outcomes
At baseline, participants were asked about the occurrence of falls during the preceding months and at follow-up examinations about the occurrence of falls since the preceding examination. Participants who reported having fallen were asked about the number of falls. At each follow-up visit, those who reported at least two falls in the last 2 years were classified as fallers.
For fractures, participants were asked identically at baseline and at each follow-up examination about the occurrence of fractures with and without hospitalization, during the two preceding years. All body sites were considered as follows: hip, wrist, spine (including compression), upper limb (arm, shoulder, and collarbone), lower limb, and any other site. The outcome was defined as reporting at least one fracture in the last 2 years.
Antidepressant exposure
At baseline and follow-up examinations, the questionnaire included an inventory of all drugs regularly used during the preceding month. To reduce underreporting, participants were asked to provide medical prescriptions, drug packages, and any other relevant material. Drug exposure has previously been validated in this cohort in comparison with the reimbursement data from the health care insurance system [22, 23] . The drugs were systematically coded using the Anatomical Therapeutic Chemical (ATC) classification system. Participants treated with antidepressants other than SSRIs were excluded from the analyses. SSRI drugs included the following: citalopram (N06AB04), fluoxetine (N06AB03), fluvoxamine (N06AB08), paroxetine (N06AB05), and sertraline (N06AB06).
We also examined the chronicity of use over the 4 years of follow-up; the analysis compared the group of participants reporting SSRI use at baseline and at both follow-up visits (the group is referred to hereafter as the Bcontinuing group^) and the group of those reporting SSRI use only at baseline (Bdiscontinuing group^) with the group of those never treated with any antidepressants (Bnever users^).
Socio-demographic and clinical variables
The standardized interview included questions on sociodemographic characteristics, smoking, visual and hearing impairment, difficulties standing up from a chair, problems of balance during walking, fear of falling, excessive daytime sleepiness, and cardiovascular pathologies. Osteo-articular pain included reported pain or treatment with anti-inflammatory or antirheumatic agents. Use of benzodiazepines and other drugs acting on the central nervous system (CNS) and the total number of other medications were derived from reported drugs. For the fracture study, use of anti-osteoporosis drugs (calcium, bisphosphonates, vitamin D, calcitonin, raloxifene, and teriparatide), hormonal replacement therapy, and corticosteroids were also considered. A hierarchical indicator of disability [24] combined three scales: Rosow and Breslau mobility scale [25] , Lawton-Brody Instrumental Activity of Daily Living (IADL) scale [26] , and Katz's Activity of Daily Living (ADL) scale [27] . This indicator defines four levels of disability: full independence, mild disability (only mobility restriction), moderate disability (mobility and IADL restriction), and severe disability (mobility, IADL, and ADL restriction). Cognitive impairment was defined as a Mini-Mental State Examination (MMSE) score <26 [28] . Severity of depressive symptoms was assessed by the Center for Epidemiologic Studies-Depression scale (CES-D) [29] , and history of major depressive episode (MDE) was diagnosed using the Mini International Neuropsychiatric Interview [30] . Orthostatic hypotension was defined as a blood pressure reduction of at least 20 mmHg systolic or 10 mmHg diastolic between lying and standing positions. Low standing blood pressure (LSBP) was defined as ≤90/60 mmHg [31] and body mass index (BMI) as weight divided by height squared.
Statistical analyses
Comparison of baseline characteristics between included and excluded participants was performed using chi-square tests and Wilcoxon rank-sum tests. Two main outcomes were examined in this study, i.e., the occurrences of falls and fractures. To avoid reverse causality and clarify temporality, we only considered the subjects who did not report the outcome of interest in the period preceding inclusion. The risk associated with SSRI use was evaluated using Cox models with delayed entry taking age as the basic time scale and birth as the time origin. Results were expressed as hazard ratios (HR) with 95 % confidence intervals (CI). This method enables a better adjustment for age and is preferred, especially for an elderly sample, over the standard model which uses study time as the time scale [32] . The assumptions of proportional hazards over time and the linearity of continuous covariates were verified.
To control for confounding effects, three nested models were constructed. Model 0 was adjusted for gender, center, and age (time scale). Model 1 included additional covariates that were associated with fall or fracture incidence (p < 0.20 in model 0). This model thus included 14 and 7 additional covariates for fall and fracture outcomes, respectively. Model 2 further included potential mediators such as poor balance and daytime sleepiness. These models were performed for participants with no missing data on any of the covariates. All analyses were conducted using the statistical software SAS version 9.4 for Windows.
Results
The median time of follow-up (interquartile range) was 3.6 (3.4-3.8) years. Regarding falls, 19.3 % of the 6599 participants declared having fallen at least twice at the 2-year (10.2 %) or 4-year follow-up (9.1 %). The differences between fallers and non-fallers adjusted for age, sex, and center are shown in Table 1 . Nearly all baseline characteristics were associated with fall incidence, except for visual impairment, orthostatic hypotension, LSBP, and benzodiazepine use. Regarding fractures, 9.5 % of the 6823 participants had at least one fracture over the follow-up: 4.5 % at 2 years and 5.0 % at 4 years. Table 2 presents the differences between participants who reported a fracture and those who did not. Participants with incident fracture were significantly older, more often women, non-smokers, and users of CNS and antiosteoporosis drugs and had more frequently a history of MDE. Table 3 gives the risk of falls at follow-up for baseline SSRI intake compared with no antidepressant intake. The same pattern of associations was found in minimally adjusted (model 0) and multi-adjusted (model 1) models. SSRI intake was significantly associated with a higher risk of falls (HR, 95 % CI = 1.58, 1.23-2.03). Further adjustments for possible mediators (poor balance during walking and daytime sleepiness) did not change the results (HR, 95 % CI = 1.62, 1.23-2.12, p < 0.001). No interaction was found between SSRI intake and gender (p = 0.44). In the analysis by SSRI drugs, citalopram was associated with the highest adjusted hazard ratio for falls (HR, 95 % CI = 2.31, 1.35-3.96) although it was not the most commonly prescribed SSRI. We then examined the risk of falls according to the pattern of SSRI use during the 4 years. Compared to the group of Bnever users,^an increased adjusted (Table 4) after multiple adjustments (HR, 95 % CI = 1.61, 1.16-2.24); further adjusting for poor balance did not modify the result (HR, 95 % CI = 1.63, 1.18-2.27). No interaction was found between SSRI use and gender (p = 0.60) or anti-osteoporosis drug use (p = 0.22). The most prescribed SSRI drugs were paroxetine and fluoxetine; however, only fluoxetine was associated with a twofold increase in the risk of fractures (multi-adjusted HR, 95 % CI = 2.07, 1.28-3.32). In the multivariate analysis of the fracture risk according to the pattern of SSRI use during the 4 years, compared to the group of never users, an increased risk was found for the continuing group (HR, 95 % CI = 1.78, 1.15-2.78).
Discussion
In this large prospective study, we found a very significant increase of about 60 % in the 4-year risk of falls and fractures for participants taking SSRIs at baseline and an even greater increase (around 80 %) in chronic users. These associations remained significant after adjustment for a large range of other confounders. Conversely, the risk was not significant after treatment discontinuation. Examining individual SSRI drugs, a more than twofold increased risk was found for falls in citalopram users only and for fractures in fluoxetine users.
A higher risk of falling has already been reported with SSRIs in distinct settings, a nursing home sample [33] , elderly patients from a primary care database [13] , and communitydwelling older women [34] . Falls are highly multi-factorial, and in contrast with most previous studies, we adjusted for a large range of potential confounders including disability, difficulties standing up from a chair, osteo-articular pain, fear of falling, systolic blood pressure, and cardiovascular diseases as well as use of benzodiazepines, other CNS drugs, and polymedication. As depression is a well-known risk factor for falls, we also adjusted for residual depressive symptoms (including low energy, fatigue, attention difficulties,…) and severity using a validated scale and a diagnostic instrument for lifetime MDE. We actually found that depressive symptomatology was the main confounder together with fear of falling and disability which have rarely been considered before. In our multi-adjusted analysis, the hazard ratio for SSRI users remained high and significant suggesting that the SSRIs themselves rather than the underlying burden of illness are independently associated with the risk of falls. This effect on falls appeared lowered in participants who discontinued treatment in the first 2 years. Other findings showed that regardless of the antidepressant class, the risk of falls increased shortly after treatment initiation and then decreased, with a peak within 8 months for SSRIs [16] . In this elderly sample, fluoxetine and paroxetine were the most frequently prescribed antidepressants and although fluoxetine has the highest half-life elimination time, we found no significant differences for the risk of falls between these two SSRIs (data not shown). Conversely, despite lower statistical power, the risk of falling with citalopram was highly significant. This has also been reported in elderly patients from a primary care database [13] and further stresses that different SSRI drugs may have distinct effects on the risk of falls.
The temporality and possible reversibility of the risk after treatment discontinuation observed in this longitudinal study, together with the consistency of the associations in different populations and settings and possible dose effects [35] , lend support to a causative link between SSRIs and falls in the elderly. We hypothesized a number of reasons for this effect. Serotonergic adverse effects include digestive symptoms, headache, restlessness, tremors, dizziness, anxiety, and weakness [6, 36] ; SSRIs also have sedative effects but this is more frequent in patients taking TCAs [37] . Poor sleep efficiency is common with SSRIs, with long sleep latency and sleep fragmentation, resulting in multiple long wake episodes [38] which could lead to elderly people getting out of bed at night, thus increasing the risk of falls. Visual function is also a key risk factor for falls [39] and SSRIs may be associated with adverse ocular effects [40] . In our large cohort, we were able for the first time to examine many of these potential mediating factors, e.g., orthostatic hypotension, LSBP, poor balance and daytime sleepiness, and visual impairment as well as headache, anxiety, and osteoporosis (data not shown), but they all failed to explain even partially the observed relationships.
Long-term SSRI treatment has been linked to osteoporosis in late life [41] which together with falls is a common pathway leading to fractures. A higher risk of fractures has previously been reported in SSRI users, with a duration-and dosedependent effect; the higher the doses, the longer the use and the higher the risk [10, 11, 14, 42, 43] . However, most studies using administrative data, could not fully control for important confounders such as osteoporosis and related factors, e.g., use of anti-osteoporosis drugs and supplements (e.g., calcium, vitamin D or hormone therapy in women) and smoking. The role of depression has also not been taken into account. However, people with long-term history of depression may have lower physical activity or performances and poorer nutritional status which could be associated with fractures [44] . In our study, we were able to adjust for both history of depression, behavioral characteristics, and use of antiosteoporosis drugs and supplements, yet SSRI use was still associated with a 60 % increased risk of fractures, reaching 80 % in long-term users. These results thus provide further support for a causative link between SSRI intake and fractures in community-dwelling elderly people. We also found that fluoxetine increased the risk of fractures but not paroxetine which was just as frequently prescribed. The fact that citalopram was a risk factor for falls and fluoxetine for fractures remains to be elucidated but suggests that fractures are not a simple consequence of falling and could indicate differences in the nature and severity of adverse reactions.
Serotonin is found in the blood platelet, the gastrointestinal tract, and the CNS and has been implicated in various physiological functions. Peripheral serotonin has been implicated in platelet aggregation, vascular tone, hypertension, and intestinal motility. In the CNS, serotonin has been associated with mood, temperature regulation, circadian rhythm, vomiting, and energy balance. Regulation of bone metabolism is complex, involving different signaling pathways, and opposite functions. Brainderived serotonin increases osteoblast numbers and decreases bone resorption, therefore increasing bone mass. Conversely, gut-derived serotonin acts to inhibit bone formation and increased circulating serotonin has been associated with lower bone density [45] . Age-related changes in drug absorption, metabolism, and blood-brain barrier permeability may also influence levels of serotonin. Depending on their pharmacological properties and bioavailability, and degree of serotonin reuptake inhibition, SSRIs may have distinct effects on bone.
Strengths of this study include its multi-centric longitudinal design and the size of the sample with more than 6500 elderly participants from the general population. Antidepressant use was ascertained at baseline and during follow-up by examining the prescriptions and boxes, thus minimizing exposure misclassification. Exposure to both current and chronic antidepressant medications has previously been shown within this cohort to be highly valid in comparison with the reimbursement data from the health care insurance system [22, 23] . Although in observational studies, residual confounding may always subsist, our analyses overcame several limitations of previous studies. History of falls or fractures can be both a predictor and a possible risk factor for depression and studies are exposed to reverse causality. In our longitudinal study, the temporality of the associations has been addressed by excluding the participants with falls or fractures in the period preceding inclusion and restricting analyses to incident falls or fractures. To our knowledge this is also the first study which adjusted for such a large range of different key factors including blood pressure, physical and activity limitations, as well as physical and mental health.
Our study has several limitations. As in most previous observational studies, falls and fractures were self-reported. We however excluded prevalent and incident cases of dementia to avoid unreliable responses and potential overestimation of the association since behavioral disturbances in dementia are a major cause of falls. In addition, incident falls were retrieved from two questions and covered a 2-year period which may lead to underreporting. No data were available on the duration of the treatment before inclusion but we were able to evaluate the effect of long-term treatment during the follow-up. Poor balance and daytime sleepiness were also self-reported. We were not able to consider specific insomnia criteria such as frequent night awakenings and also some aspects of the visual functioning including contrast vision. Another potential limitation is that we did not use propensity score methods in our analyses to account for confounders. However, it should be noted that these methods do not always adequately account for unmeasured confounders. They estimate marginal effects at a population level while multivariate models as used in this study estimate individual conditional effects [46] and are more suitable for explanatory investigations with the additional advantage of allowing the evaluation of the impact of mediating factors.
In conclusion, this study showed that in communitydwelling elderly people, SSRI users are at high risk of falls and fractures. These associations are not due to reverse causality or residual depressive symptoms. The possible pathways explaining these associations remain to be explored. Differences may exist between SSRI drugs regarding the risk of falls and fractures. Precautions taken when prescribing TCAs to elderly patients should be extended to SSRIs along with an objective diagnosis of depression, an adapted treatment, and an evaluation of risk factors for falls and fractures.
